OpenAI Launches GPT-Rosalind AI Model to Speed Up Drug Discovery

OpenAI launched GPT-Rosalind on April 17, 2026, a new AI model designed to accelerate drug discovery by reducing the 10–15 year U.S. drug approval timeline. Available via ChatGPT, Codex, and API, it aims to speed up early-stage research, connecting to over 50 tools to enhance biological research.

Chainshorts summarizes news into 60-word briefs. Full article is owned and hosted by CoinCentral. Read the original via the link above. Chainshorts users earn SKR for reading in the app.